Hereditary Angioedema (HAE)
58
6
10
38
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Published Results
22 trials with published results (38%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 58 trials
100.0%
+13.5% vs benchmark
36%
21 trials in Phase 3/4
58%
22 of 38 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 38 completed trials
Clinical Trials (58)
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries
A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of Saudi Arabia
A Study of Navenibart in Participants With Hereditary Angioedema
A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
Donidalorsen Treatment in Children With Hereditary Angioedema
A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea
HAE Burden and Crisis Management
A Phase 2 in Adult Subjects With Hereditary Angioedema
A Survey of Lanadelumab in Participants With Hereditary Angioedema
A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema
A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema
A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China
A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema
A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)
A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema